CGX Chromogenex

    RNS Number : 9981Z
  Chromogenex PLC
  28 July 2008
   

    

    Chromogenex plc
    (the 'Company)



    FDA approval for the Chromolite EP


    Chromogenex Plc ('the Company') is pleased to announce that it has now received Section 510(K) approval from the Food and Drug
Administration to market and sell its Chromolite EP ( Enhanced Pulse), the newest version of Chromolite, in the United States.

    Chromolite EP is a state-of-the-art Intense Pulsed Light System used for the treatment of unwanted hair, photo rejuvenation and active
acne. Chromolite EP is specially designed for use within a clinic or medspa environment in a single portable device. 

    Peter McGuinness, Chairman, commented: "We are delighted to have received FDA approval for our latest version of the Chromolite product.
With the US currently accounting for approximately 50 per cent of the world healthcare market and the Chromolite representing approximately
40 per cent. of the Company's sales, this is a significant achievement in helping drive further revenues for the Company."






    Chromogenex PLC                                        Tel: +44 20 8434 0540
    Peter McGuinness, Chairman

    HB Corporate
    Luke Cairns                                                      Tel: +44 (0)20 7510 8600
                            
    Threadneedle Communications
    Graham Herring/Alex White                           Tel: +44 (0)20 7936 9605 


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCFKFKBKBKDAOB

Chromogenex (LSE:CGX)
Historical Stock Chart
From May 2024 to Jun 2024

Chromogenex (LSE:CGX)
Historical Stock Chart
From Jun 2023 to Jun 2024